ACAM-FLU-A

Overview
ACAM-FLU-A is a vaccine, being developed by Acambis, which is intended to provide lifelong protection against all strains of Influenza A. The vaccine targets the M2 protein which is found on the surface of all strains of Influenza A.

The vaccine has been tested in a human trial, in the United States, where it is claimed to have successfully protected 90% of individuals against the flu virus. Further human trials are planned.